ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates

Court: S.D. California

Case: 23-CV-01216

ImmunityBio IBRX has signed an MOU with Saudi Arabia’s Ministry of Investment, King Faisal Specialist Hospital, and KAIMRC to introduce its Cancer BioShield platform across the Middle East. Powered by Anktiva—the world’s first FDA-approved IL-15 superagonist—the platform aims to restore and activate the immune system rather than suppress it. This expansion marks a major step toward making immune-restorative therapies more globally accessible.

More news for IBRX investors—check what you might be missing right now.

At the same time, IBRX agreed to a $10.5M settlement with investors over claims that it misled them about manufacturing deficiencies which led to the FDA’s rejection of its Anktiva Biologics License Application.

You can check more information about it and file for a payout here.